The Shkreli Pill — searchable YouTube transcripts & AI Q&A

Moderna's Downside Isn't Over, Chip Stock Valuations Are Fooling You, Palantir Stock |Martin Shkreli

Martin Shkreli argues that Moderna's downside isn't over, despite it being a real company with a significant drug, and suggests there's more downside risk. He also criticizes semiconductor stock valuations, noting that buying or selling based on valuation is a mistake, and shares a list of axioms for semiconductor investing, including that product cycles often drive EPS higher and last longer than expected. He advises traders to size positions based on the rarity of the opportunity, comparing it to poker, and warns against forcing trades with too much capital.

Tesla & Netflix Decide Where the Market Goes Next. Moderna Short Analysis, IonQ Stock Martin Shkreli

The speaker argues that Moderna's stock is overvalued, even if its cancer vaccine becomes one of the best-selling drugs ever. He models the potential revenue from the melanoma indication and shows that even with $35 billion in annual sales, the stock is only fairly valued, making it a short candidate. He also notes that the RSV vaccine is underperforming and that competition from Merck and other players adds risk.

My Apple Position Revealed, Testing Godel's New AI Trading Assistant, Oracle, Intel | Martin Shkreli

Martin Shkreli tests Godel, an AI trading assistant, and finds it can execute orders but struggles with canceling them and lacks safeguards against large market orders, as shown when it confirms a 10 million share Microsoft buy without checking buying power. He also demonstrates that the AI correctly refuses to act on material non-public information, but can be tricked into compliance with a fake clearance. Shkreli criticizes a colleague's semiconductor trading as lacking a thesis and beta hedging, and shares his view that math and programming may become less relevant as AI advances.

How Cramer Knew the Tech Bubble Was Over. Reality Check for My Callers | COMPILATION |Martin Shkreli

Shkreli argues that investors should avoid trend-following and instead focus on finding undervalued, undiscovered companies or disruptive technologies, citing his experience with enzyme replacement therapy stocks like Spruce Bioscience. He warns against buying stocks based on hype, such as space companies with high valuations and low revenue, and emphasizes the importance of having multiple investment strategies.

Anthropic's Revenue Should Scare You. Jensen About Coreweave, Oracle Stock | Martin Shkreli

Shkreli argues that Anthropic's 50% quarter-over-quarter revenue growth is spectacular but may not satisfy the market, which expected even higher numbers, and he warns that such rapid growth can eventually slow. He also discusses Coreweave's stock decline and the possibility of an Nvidia bailout, suggesting that Jensen Huang's comments may provide confidence but not fully resolve the company's debt concerns. He notes that the market's panic might be a buying opportunity, though he remains cautious.